Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Sinead ToomeyAlexander J EustaceJoanna FayKatherine M SheehanAoife CarrMalgorzata MilewskaStephen F MaddenAusra TeiserskieneElaine W KayNorma O'DonovanWilliam GallagherLiam GroganOscar BreathnachJanice WalsheCatherine KellyBrian MoultonM John KennedyGuiseppe GulloArnold D HillColm PowerDeirdre DukeNiamh HamblyJohn CrownBryan T HennessyPublished in: Breast cancer research : BCR (2017)
ClinicalTrials.gov, NCT01485926 . Registered on 2 December 2011.